Metformin improves survival in patients with pancreatic ductal cancer and diabetes

Metformin improves survival in patients with pancreatic ductal cancer and diabetes

Metformin improves survival in patients with pancreatic ductal adenocarcinoma and pre-existing diabetes, reports this month’s American Journal of Gastroenterology . Dr Aimee Lucas and colleagues from New York, USA investigated whether metformin use before pancreatic ductal adenocarcinoma diagnosis affected survival of patients with diabetes mellitus, controlling confounders such as diabetic severity.